Indoco Remedies Announces 79th AGM on Sep 17, 2026, with Dividend Recommendation
Indoco Remedies will hold its 79th AGM on September 17, 2026, via VC/OAVM. The company recommended a final dividend of ₹0.20 per equity share for FY2025-26, subject to shareholder approval. The Record Date is September 10, 2026, and Book Closure is from September 11-17, 2026.
The announcement pertains to a routine AGM and a small dividend payout, which are standard corporate events and are unlikely to have a significant impact on the company's stock price or market perception.
The announcement is a routine procedural update regarding the Annual General Meeting and dividend declaration, with no significant positive or negative financial news.
Indoco Remedies Limited has announced that its 79th Annual General Meeting (AGM) will be held on Thursday, September 17, 2026, at 10:30 a.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) in compliance with current regulations.
The company has also informed about the Book Closure period, which will be from Friday, September 11, 2026, to Thursday, September 17, 2026, inclusive. This period is for the AGM and the payment of the final dividend for the financial year 2025-2026.
During a board meeting held on May 07, 2026, the directors recommended a final dividend of ₹0.20 per equity share for the financial year ended March 31, 2026. This dividend is subject to the approval of the shareholders at the upcoming AGM. If approved, the dividend will be paid within 30 days from the AGM date via electronic mode. The Record Date for determining the entitlement to this dividend has been set as Thursday, September 10, 2026.
The company is also providing detailed instructions for members to register or update their email addresses and bank account details, especially for those holding shares in physical form, to facilitate electronic dividend payments and ensure compliance with tax regulations. The notice of the AGM and the Annual Report for FY 2025-2026 will be sent electronically to members whose email addresses are registered.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.